| 纳入研究 | 年份 | 样本量(实验组/对照组) | 实验组干预 方案 | 对照组干预 方案 | 强迫症状 评估工具 | 心理灵活性评估工具 |
| Key等(Key et al., 2017) | 2017 | 28 (13/15) | MBCT | WLC | YBOCS | - |
| Mathur等(Mathur et al., 2021) | 2021 | 60 (30/30) | MBCT | SMT + 其他治疗 | YBOCS | AAQ |
| Twohig等(Twohig et al., 2010) | 2010 | 69 (36/33) | ACT | PRT | YBOCS | AAQ |
| Rohani等(Rohani et al., 2018) | 2018 | 32 (16/16) | ACT + SSRI | SSRI | YBOCS | AAQ |
| Twohig等(Twohig et al., 2018) | 2018 | 49 (24/25) | ACT + ERP | ERP | YBOCS | AAQ |
| Vakili等(Vakili et al., 2015) | 2015 | 17 (9/8) | ACT | SSRI | YBOCS | - |
| Zemestani等(Zemestani et al., 2022) a | 2022 | 25 (13/12) | ACT + SSRI | ERP + SSRI + 其他治疗 | YBOCS | - |
| Zemestan等(Zemestani et al., 2022) b | 2022 | 28 (13/15) | ACT + SSRI | WLC | YBOCS | - |
| Zhang等(Zhang et al., 2021) a | 2021 | 43 (15/28) | MBCT + SSRI | PE + 其他治疗 | YBOCS | - |
| Zhang等(Zhang et al., 2021) b | 2021 | 44 (15/29) | MBCT + SSRI | SSRI | YBOCS | - |
| Baghooli等(“ | 2014 | 50 (25/25) | ACT | 氯丙咪嗪 | YBOCS | - |
| Baghooli等(“ | 2014 | 50 (25/25) | ACT + 氯丙 咪嗪 | 氯丙咪嗪 | YBOCS |
|